CSN Login
Members Online: 5

You are here

Looking for experience with Herceptin-Perjeta (pertuzumab-trastuzumab)

Telephone number: 
Friday, March 23, 2018 - 10:45am
Last Name: 
First Name: 
Announcement removal date: 
Friday, April 20, 2018 - 10:00am
Have you submitted an announcement request to CSN in the past?: 
Your announcement.: 

My name of MJ DeCoteau and I am the executive director of Rethink Breast Cancer (www.rethinkbreastcancer.com) – a Canadian patient group dedicated to building community for young women dealing with breast cancer and providing support and resources to help them live the best quality of life.

We are looking for woman with HER2-positive early breast cancer and women who have been treated with Herceptin-Perjeta (pertuzumab-trastuzumab) combination therapy to talk about their treatment experience. We welcome feedback from women in the United States and other countries.

The Canadian government will soon be reviewing the use of Herceptin-Perjeta to treat HER2-positive early breast cancer that is node-positive or hormone receptor-negative, and Rethink Breast Cancer will be making a submission to ensure that patient voices are represented and considered during the review process.

If you are interested in talking about your experiences, we would like to ask you to complete this survey: https://www.surveymonkey.com/r/R76HZXY

If you would like to speak with us directly about your cancer or treatment experience, you can contact Shawna Rich-Ginsberg at shawna@rethinkbreastcancer.com.

We would also like to invite your family or friends to talk about their experience caring for a patient being treated with ribociclib: https://www.surveymonkey.com/r/RD79RF3

MJ DeCoteau

Founder + Executive Director

Rethink Breast Cancer


The above announcement posted on Cancer Survivors Network is intended to be informational in nature. The American Cancer Society does not warrant or guarantee the accuracy of the information provided and will not oversee or otherwise be involved in the conduct of the actual research study.  We recommend that you consult with your health care provider if you have concerns about your health before participating in any research study.  Any information you obtain through CSN announcements should not be used as a substitute for consultation with your health care provider.

Check the appropriate category for your announcement: 
Research study, clinical trial, focus group,etc (Requires IRB review and certification. See here for guidelines.)
Contact - Email: 
Contact - First name: 
Contact - Last name: 
Subscribe to Comments for "Looking for experience with Herceptin-Perjeta (pertuzumab-trastuzumab)"